s
Independent financial analysts widely recognize this progress:
“ZIOP continues to make progress with respect to the company-sponsored TCR-T program, the Controlled IL-12 program, and the Sleeping Beauty CAR-T program.”
2
“By unlocking the potential of its Sleeping Beauty technology, the Company is poised to deliver a leap forward in the personalization of cancer therapy.”
3
“We think that the company continues to make forward progress across its various platforms (TCR-T, CAR-T, and controlled IL-12).ZIOP has executed well over 2020 in curating immune receptors from its own libraries and it is moving forward its wholly owned program.”
4
The Company continues to urge shareholders to support Ziopharm’s continued progress and protect the value of their investment by signing and returning the